In search of innovative techniques to evaluate pharmaceutical R&D projects

Technovation

Volumn 23, Issue 4, 2003, Pages 291-296

  Jacob, William F ^a   Kwak, Young Hoon ^b  

^a GLAXOSMITHKLINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Project management; R D; Real option models; Risk management

Indexed keywords

COSTS; DRUG PRODUCTS; HEALTH CARE; MARKETING; PROJECT MANAGEMENT; RISK MANAGEMENT;

REAL OPTION MODELS;

RESEARCH AND DEVELOPMENT MANAGEMENT;

EID: 0037399741     PISSN: 01664972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4972(01)00116-X     Document Type: Article

References (44)

1. Agnew, B., 2000. When pharma merges, R&D is the dowry. Science, 17 March, 1952-1953.
2. Angelis D.I. Capturing the option value of R&D. Research Technology Management. 4:2000;31-34.
3. Badiru A.B., Pulat P.S. Comprehensive Project Management: Integrating Optimization Models, Management Principles, and Computers, pp. 1-548. 1995;Prentice-Hall, Englewood Cliffs, NJ.
4. Bettis R., Hitt M.A. The new competitive landscape. Strategic Management Journal. 16:1995;7-19.
5. Black, F., Scholes, M., 1988. The pricing of options and corporate liabilities. Journal of Political Economy May-June, 15-22.
6. Boer F.P. The Valuation of Technology. 1999;John Wiley & Sons, New York.
7. Bone S., Saxon T. Developing effective technology strategies. Research Technology Management Washington. 4:2000;50-58.
8. Byers L. U.S. pharmaceutical industry: a standard for success. Project Management Journal. 3:1989;11-12.
9. Carr, G., 1998. Survey: The pharmaceutical industry: beyond the behemouths. The Economist 8056 (21 Feb), S16-S18.
10. Cooper R.G., Edgett S.J., Kleinschmidt E.J. New problems, new solutions: making portfolio management more effective. Research Technology Management. 2:2000;18-33.
11. Day G.S., Schoemaker P.J.H. Avoiding the pitfalls of emerging technologies. California Management Review. 2:2000;8-33.
12. Duncan, W.R., 1996. A guide to the project management body of knowledge. Project Management Institute, Newtown Square, PA.
13. Edleson, M.E., 1994. Real options: valuing managerial flexibility (A). HBS Teaching note #9-294-109.
14. Fagan, P.L., Hayes, R.H., 1998. The pharma giants: ready for the 21st century? Harvard Business School Publishing, Boston, 6 May, pp. 1-34.
15. Foulkes, J., 2000. Art or science? How - and even does - the pharmaceutical industry apply the discipline of project management? Proceedings of PMI Research Conference 2000.
16. Frame J.D. The New Project Management, pp. 1-328. 1994;Jossey-Bass, San Francisco.
17. Gershon D. Are mega-mergers good medicine for the pharmaceutical industry? Nature. 405:2000;257-258.
18. Graves S.B., Ringquest J.L., Case R.H. Formulating optimal R&D portfolios. Research Technology Management. 3:2000;47-51.
19. Henriksen A.D., Traynor A.J. A practical R&D project-selection scoring tool. IEEE Transactions on Engineering Management. 2:2000;158-170.
20. Herath H.S.B., Park C.S. Economic analysis of R&D projects: an options approach. The Engineering Economist. 1:2000;1-35.
21. Ibbs C.W., Kwak Y.H. Assessing project management maturity. Project Management Journal. 1:2000;32-43.
22. Jagle A.J. Shareholder value, real options, and innovation in technology-intensive companies. R&D Management. 3:1999;271-287.
23. Jarrett E.L. The role of risk in business decision-making, or how to stop worrying and love bombs. Research Technology Management. 6:2000;44.
24. Kaufman, M., 2000. Deaths spur bowel drug withdrawal. Washington Post, 29 Nov, A01.
25. Kearney, A.T., 1997. Maximizing pharmaceutical health in the next millennium: a prescription for increased shareholder value. The Economist (20 Sept), 67-68.
26. Krusko D., Cangemi R.R. The utilization of project management in the pharmaceutical industry. Journal of the Society of Research Administrators. 1:1987;17-24.
27. Lint O., Pennings E. R&D as an option on market introduction. R&D Management. 4:1998;279-287.
28. Luehrman T.A. Strategy as a portfolio of real options. Harvard Business Review. 5:1998;89-99.
29. McGahan, A.M., 1994. Industry structure and competitive advantage. Harvard Business Review, November-December, 115-124.
30. McGahan, A.M., Coxe, D.O., Keller, G., McGuire, J., 1995. The pharmaceutical industry in the 1990s. Harvard Business School, Boston, MA.
31. McGrath R.G. A real options logic for initiating technology positioning investments. Academy of Management Review. 4:1997;974-996.
32. McGrath R.G., MacMillan I.C. Assessing technology projects using real options reasoning. Research Technology Management. 4:2000;35-49.
33. Mirasol F. Pharma's market consolidation creates new kind of player. Chemical Market Reporter. 22:2000;5.
34. Mirasol F. M&As continue to accelerate in global pharma industry. Chemical Market Reporter. 14:2000;6-14.
35. Murphy P.L. Pharmaceutical project management - is it different? Project Management Journal. 3:1989;35-38.
36. Nichols, N.A., 1994. Scientific management at Merck: an interview with CFO Judy Lewent. Harvard Business Review January-February, 91.
37. Perdue R.K., McAllister W.J., King P.V., Berkey B.G. Valuation of R and D projects using options pricing and decision analysis models. Interfaces. 6:1999;57-74.
38. Perlitz M., Peske T., Schrank R. Real options valuation: the new frontier in R&D project evaluation? R&D Management. 3:1999;225-269.
39. Reiss A. Investment in innovations and competition: an option pricing approach. Quarterly Review of Economics and Finance. 38:1998;635-650.
40. Royer P.S. Risk management: the undiscovered dimension of project management. Project Management Journal. 1:2000;6-13.
41. Sharpe P., Keelin T. How SmithKline Beecham makes better resource-allocation decisions. Harvard Business Review. 2:1998;52.
42. Sheasley W.D. Taking an options approach to new technology development. Research Technology Management. 6:2000;37.
43. Tritle G.L., Scriven E.F.V., Fusfeld A.R. Resolving uncertainty in R&D portfolios. Research Technology Management. 6:2000;47.
44. Ward S. Requirements for an effective project risk management process. Project Management Journal. 3:1999;37-43.